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Abstract
Background: The inter-relationships of atrial fibrillation (AF) to retinal vascular occlusions (whether retinal artery
occlusion (RAO) or retinal venous occlusion (RVO)) remain unclear. It is unknown if a presentation of retinal artery or
venous occlusions may indicate a new onset cardiac arrhythmia. To shed light on this association, we investigated
the risk of new onset AF in patients with known RAO and RVO.
Methods: Patients with retinal occlusions from 1997 to 2011 were identified through Danish nationwide registries
and matched 1:5 according to sex and age. Cumulative incidence and unadjusted rates of AF according to retinal
vascular occlusions (i.e. RAO or RVO) were determined. Hazard ratios (HR) of AF according to retinal vascular
occlusion were adjusted for hypertension, diabetes, vascular disease and prior stroke/systemic thromboembolism/
transient ischemic attack.
Results: One thousand three hundred sixty-eight cases with retinal vascular occlusions were identified (median age
71.4 (inter quartile range (IQR); 61.2–79.8), 47.3% male). RAO constituted 706 cases (51.6%) and RVO 529 (38.7%). The
rate of incident AF amongst all cases with retinal vascular occlusion was 1.74 per 100 person-years (95% confidence
interval (CI), 1.47–2.06) compared to 1.22 (95% CI, 1.12–1.33) in the matched control group. The rate of AF in RAO
was 2.01 (95% CI, 1.6–2.52) and 1.52 (1.15–2.01) in RVO. HRs of incident AF adjusted for cardiovascular comorbidities
were 1.26 (95% CI; 1.04–1.53, p = 0.019) for any retinal vascular occlusion, 1.45 (95% CI; 1.10–1.89, p = 0.015) for RAO,
and 1.02 (95% CI; 0.74–1.39, p = 0.920) for RVO.
Conclusions: A new diagnosis of retinal vascular occlusion in patients without prior AF was associated with
increased risk of incident AF, particularly amongst patients with RAO. Awareness of AF in patients with retinal
vascular occlusions is advised.
Keywords: Epidemiology, Retinal artery occlusion, Retinal vein occlusion,, Atrial fibrillation
Background
Retinal artery and vein occlusions (RAO and RVO) are
common causes of retinal vascular disease. The patho-
genesis of RVO is mainly considered to be thrombus for-
mation, whereas embolisms result in RAO. [1] Atrial
fibrillation (AF) is not included amongst the known risk
factors for RVO. [2] The embolic source in patients with
RAO is thought to be the carotid artery or valvular
disease, but patients with AF are at increased risk of de-
veloping RAO. [1, 3] Both conditions are associated with
cardiovascular risk factors, such as hypertension and dia-
betes mellitus. [4–9] Similarly, patients with RAO and
RVO are at increased risk of thrombosis-related compli-
cations such as myocardial infarction and stroke as well
as silent brain infarction. [2, 10–16]
Ischemic stroke is an episode of neurological dysfunc-
tion caused by focal cerebral, spinal, or retinal infarction.
[17] This definition of ischemic stroke applies to current
guidelines, and implies that the work-up of patients with
retinal vascular occlusions (i.e. RAO or RVO) should
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include a careful evaluation of cardiovascular risk fac-
tors. [6, 18, 19] While it has been argued that embolisms
arising in the atria are too large to cause RAO, [20]
valvular heart disease, as well as AF, may be risk factors
for RAO. [11, 21–23] As AF is often asymptomatic, sub-
clinical (silent) AF could represent the underlying cause
in RAO patients without known AF,
Guidelines recommend treatment with anticoagulation
to decrease the risk of ischemic stroke in patients with
AF according to the CHA2DS2-VASc (congestive heart
failure, hypertension, age > 75 years, diabetes, stroke,
vascular disease, age 65–75 and female sex score). [24–
26],. We have previously shown that retinal vascular
occlusion independently increases the risk of ischemic
stroke and thromboembolism in patients with AF. [27]
Accordingly, retinal vascular occlusion in patients with
AF may merit treatment with anticoagulation.
We hypothesized that in patients without previously
known AF, retinal vascular occlusions (i.e. RAO or
RVO) overall would be associated with increased risk of
incident AF. To explore these associations, we identified
all new cases of retinal vascular occlusion in patients
without prior AF in Denmark between 1997 and 2011 in
a nationwide cohort study. Furthermore, independent
subgroup analyses were performed for RAO and RVO.
Methods
Registers
Data was collected from the following Danish nation-
wide registers: The Danish National Patient Register
contains information regarding all hospital admissions
since 1974 classified by diagnoses according to Inter-
national Classification of Diseases (ICD). ICD-8 codes
were used from 1974 to 1995, and ICD-10 codes from
1996 onwards. [28] In the Register of Medicinal Product
Statistics, all data on dispensed prescription drugs have
been collected since 1994 coded according to The Ana-
tomical Therapeutic Chemical (ATC) Classification Sys-
tem. [29, 30] Information regarding death and cause of
death was accessed via the Danish Cause of Death Regis-
ter. [31] Finally, linkage of data between registers is pos-
sible due to the unique identification number afforded
all Danish residents.
Definition of retinal vascular occlusion, comorbidities and
outcome
RAO was identified according to ICD-8 code 37702 and
ICD-10 code H340, H341 and H342. RVO was identified
according to ICD-8 37703 and ICD-10 H348. Unspecified
retinal vascular occlusion was defined by ICD-10 code
H34 without specification of RAO or RVO. AF was identi-
fied by ICD-8 code 42793,42794 and ICD-10 code I48.
Other comorbidities established from discharge diag-
nosis were heart failure (ICD-8: 425, 4270, 4271, ICD-
10:I110,J819, I42 and I50). Prior stroke, transitory ische-
mic attack or systemic thromboembolism (ICD-8:
433,434,435,436,444, ICD-10: I63, I64DG458, G459 and
I74) and vascular disease (myocardial infarction and per-
ipheral vascular disease (ICD-8: 410, 440, ICD-10: I21,
I22, I700, I702, I703, I704, I705, I706, I707, I708 and
I709).
Preceding use of anticoagulation was identified as
redeemed prescriptions of warfarin (ATC: B01AA) prior
to index date i.e. the date of the qualifying diagnosis of
retinal vascular occlusions for cases. Index date for con-
trols were the same date as for the corresponding cases.
Medication at baseline was defined as redeemed pre-
scriptions 180 days prior to admission. Prescriptions of
any glucose-lowering drug (ATC: A10) defined diabetes
mellitus. Specific drugs identified included; clopidogrel
(ATC: B01AC04), dipyridamole (ATC: B01AC07), non-
steroidal anti-inflammatory drugs (ATC: M01A except
M01AX05), loop diuretics (ATC: C03C) and acetylsali-
cylic acid (ATC: B01AC06 and N02BA01). Notably, al-
though acetylsalicylic acid can be sold over-the-counter,
most use continues to be registered due to reimburse-
ment policies.
Hypertension was defined as concurrent treatment with
two antihypertensive drugs of different classes: antiadrener-
gic (ATC: C02A, C02B, C02C), non-loop diuretics (ATC:
C02L, C03A, C03B, C03D, C03E, C03X, C07B, C07C,
C07D, C08G, C02DA, C09BA, C09DA and C09XA52), va-
sodilators (C02DB, C02DD and C02DG), beta blockers
(C07A, C07B, C07C, C07D and C07F), calcium channel
blockers (C08, C07F, C09BB and C09DB), and renin angio-
tensin system inhibitors (ATC: C09AA, C09BA, C09BB,
C09CA, C09DA, C09DB, C09XA02 and C09XA52). This
method has previously been validated. [26]
Study population and outcomes
All patients with discharge diagnosis of retinal vascular
occlusions (i.e. RAO and RVO) from January 1st 1997 to
December 31st 2011 were identified. Patients with pre-
vious AF or previous use of warfarin were excluded. Inclu-
sion in the study happened on the day of discharge of
retinal vascular occlusion. Each patient with retinal vascu-
lar occlusion was matched according to sex and age with
five controls from the Danish National Patient Register
using the Greedy Matching Macro (http://www.mayo.edu/
research/documents/gmatchsas/doc-10027248). Controls
were free from previous AF or prior use of warfarin.
Patients were followed until incident of AF, death, or end
of study period.
Statistical analysis
Rates of AF were calculated as new cases of AF per 100
person-years. Cumulative incidence was calculated tak-
ing into account the competing risk of death. Risk of AF
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according to retinal vascular occlusion was determined
by Cox regression analysis and presented unadjusted
and adjusted for hypertension, diabetes, vascular disease,
and prior stroke/systemic thromboembolism/transitory
ischemic attack. Independent subgroup analyses were
performed for RAO, RVO, and unspecified occlusions,
using the corresponding controls as reference. Fulfill-
ment of all model assumptions including proportional
hazards, goodness of fit chi-square test, and significance
of interactions between all covariates adjusted for in the
model were tested and found valid.. Data management
and statistical analyses were performed using SAS 9.2
(SAS Institute Inc., Gary, NC, USA) and R 3.0.2. (R Core
Team (2013). R: A language and environment for statis-
tical computing. R Foundation for Statistical Computing,
Vienna, Austria. URL https://www.R-project.org).
Ethics
Retrospective register based studies do not require ethical
approval in Denmark and the study was approved by the
Danish Data Protection Agency (Ref. no. 2007–58-0015
/Internal ref. no. GEH-2014-013, I-Suite number: 02731).
Results
Selection of the study population is depicted in Fig. 1.
After exclusion of patients with prior diagnosis of AF
and patients with preceding use of warfarin 1368 pa-
tients with retinal vascular occlusions remained; of these
706 (51.6%) had RAO and 529 (38.7%) had RVO. The
number of patients with an unspecified diagnosis of ret-
inal vascular occlusion (including those with both diag-
nosis of RAO and RVO on the day of inclusion) was 133
(9.7%).
The number of controls matched for sex and age was
6840. Baseline characteristics according to presence and
type of retinal vascular occlusion are summarized in
Table 1. The median age and gender distribution
amongst cases and controls was 71.4 (interquartile range
(IQR) 61.2–79.8) years and 47.3% were males. Compar-
ably, patients with retinal vascular occlusion had more
comorbidities and greater burden of cardiovascular
medication compared to controls. Patients with RAO
were slightly younger (median age 70.7 years (IQR 61.2–
78.7)) and proportionately more male (49.7%) compared
to patients with RVO (median age 73.4 years (IQR 62.3–
81.3), 45.5% males). Furthermore, RAO patients more
frequent had a history of stroke/transitory ischemic at-
tack/systemic thromboembolism, as reflected in the use
of clopidogrel and dipyridamole.
The rates of incident AF are shown in Table 2. The rate
of incident AF was higher in patients with any retinal vas-
cular occlusion compared with patients without retinal
Fig. 1 Flowchart of study population
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vascular occlusion (1.74 incidents cases of AF per 100
person-years (95% confidence interval (CI); 1.47–2.06) ver-
sus 1.22 (95% CI; 1.12–1.33)). Incident AF rate according
to type of occlusion was greater in the group with RAO (2.
01 (95% CI; 1.6–2.52)) compared to patients with RVO (1.
52 (95% CI; 1.15–2.01)).
Figures 2 and 3 show the cumulative incidence of AF
and all-cause death in patients with RAO and RVO, re-
spectively. The cumulative incidence of AF was significantly
higher amongst patients with RAO compared with controls
(p = 0.029), while no significant difference was observed be-
tween patients with RVO and the control group (p = 0.66).
Table 1 Baseline characteristics of matched population





Arterial Vein p-value for difference between retinal artery and
vein occlusion
n 1368 6840 706 529
Median age, years
(IQR)







Male 648 (47.3%) 3240
(47.3%)
* 351 (49.7%) 241 (45.6%) 0.150
Diabetes 115 (8.4%) 368 (5.4%) <
0.01
59 (8.4%) 50 (9.5%) 0.502
Heart failure 67 (4.9%) 168 (2.5%) <
0.01
34 (4.8%) 29 (5.5%) 0.599




183 (25.9%) 160 (30.2%) 0.093
Stroke/TE/TIA 257 (18.8%) 395 (5.8%) <
0.01
161 (22.8%) 62 (11.7%) < 0.01
Vascular disease 148 (10.8%) 416 (6.1%) <
0.01
92 (13%) 45 (8.5%) 0.012




277 (39.2%) 190 (35.9%) 0.234
Antiadrenergic 24 (1.8%) 61 (0.9%) <
0.01
10 (1.4%) 13 (2.5%) 0.181
Beta blockers 234 (17.1%) 753 (11%) <
0.01
113 (16%) 94 (17.8%) 0.412
Calcium channel
blockers
279 (20.4%) 831 (12.1%) <
0.01
138 (19.5%) 107 (20.2%) 0.767
Clopidogrel 22 (1.6%) 55 (0.8%) <
0.01
18 (2.5%) 3 (0.6%) < 0.01
Loop diuretics 185 (13.5%) 590 (8.6%) <
0.01
97 (13.7%) 77 (14.6%) 0.683
NSAID 235 (17.2%) 915 (13.4%) <
0.01
125 (17.7%) 84 (15.9%) 0.397




182 (25.8%) 170 (32.1%) 0.014
Dipyridamole 79 (5.8%) 108 (1.6%) <
0.01
54 (7.6%) 16 (3%) < 0.01
*=not calculated; age and sex were parameters used for matching, hence the distribution between was similar. IQR Interquartile range
Table 2 Crude rates of AF per 100 person-years according to retinal vascular occlusion
With retinal vascular occlusion
No of patients No of events Rate of AF (95% confidence interval)
Any retinal vascular occlusion 1368 135 1.74 (1.47–2.06)
No retinal vascular occlusion (total matched control population) 6840 537 1.22 (1.12–1.33)
RAO 706 74 2.01 (1.6–2.52)
RVO 529 49 1.52 (1.15–2.01)
Unspecified retinal vascular occlusion 133 12 1.45 (0.82–2.55)
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Cumulative incidence of all-cause death was also signifi-
cantly different between RAO and matched controls (p < 0.
001) and RVO and matched controls (p = 0.018).
Results from Cox regression analysis are shown in Fig.
4. The unadjusted hazard ratio (HR) of AF according to
any retinal vascular occlusion was 1.44 (95% CI; 1.20–1.
74, < 0.001), and the HR adjusted for heart failure, hyper-
tension, diabetes, ischemic stroke/systemic thrombo-
embolism/transitory ischemic attack and vascular disease
the HR was 1.26 (95% CI; 1.04–1.53, p = 0.019).
In the subgroup analyses we calculated an unadjusted
HR of AF amongst patients with RAO of 1.71 (95% CI;
1.32–2.22, p < 0.001) and adjusted HR of 1.45 (95% CI;
1.10–1.89, p = 0.015). For RVO the HRs of AF were non-
significant (1.17 (95% CI; 0.86–1.59, p = 0.315) and (1.02
(95% CI; 0.74–1.39, p = 0.923) for unadjusted and ad-
justed analysis, respectively).
Patients with unspecified retinal vascular occlusion (in-
cluding those diagnosed with coinciding artery and vein
occlusions) had a rate of incident AF of 1.45 (95% CI; 0.
82–2.55), unadjusted HR of 1.40 (95% CI; 0.74–2.65, p = 0.
296) and an adjusted HR of 1.32 (0.68–2.59, p = 0.412).
Discussion
In this register-based nationwide study of 1368 patients
with a first-time diagnosis of retinal vascular occlusion,
we found an increased risk of incident AF among pa-
tients with RAO, but not in patients with RVO. Given
that AF may have been undiagnosed at the time of RAO,
this strengthens the hypothesis that AF may in some
cases be the underlying cause of RAO.
Detection of AF
Etiologies for ischemic strokes can be classified as large-
artery atherosclerosis, small-vessel occlusion, other deter-
mined etiology, undetermined etiology or cardioembolism
according to the TOAST (Trial of Org 10,172 in Acute
Stroke Treatment) criteria. [32] Cardio-embolism is esti-
mated to be the source of stroke in 16–30% of all ischemic
strokes, and 61% in patients with AF.
In stroke patients, guidelines recommend timely diag-
nosis of AF is prioritized to ensure prescription of oral
anticoagulation to prevent future ischemic strokes. As
AF in many cases is paroxysmal, detection rate of AF
after ischemic stroke depends on the applied diagnostic
method. Using a 7-day event-recorder, AF can be de-
tected in 12.5–15% of stroke patients free of previous –
known – AF. [33, 34] The detection rate increases fur-
ther with continuous implantable and external cardiac
monitoring. [35, 36]
The association of AF and RAO is not investigated to
the same extent as the association of AF and ischemic
stroke. Whereas one study found a similar detection rate
of AF in RAO patients AF (12.5% of patients using 24-h
ECG (at least)), other studies indicate that AF is more
common in patients with ischemic stroke and find a
higher number needed to screen in patients with RAO
than in patients with ischemic stroke [14, 37, 38]. Pa-
tients with AF have a higher ratio of hemispheric to ret-
inal occlusions compared to patients with AF, which
may indicate that other embolic sources than the atria
such as a carotid stenosis play a larger role in RAO pa-
tients. [39]
No studies have however investigated the proportion
of cardio-embolic strokes in RAO. [40–42] In our popu-
lation, less than 10% of the RAO patients were diag-
nosed with AF during follow-up. Several studies suggest
assessment of cardiovascular risk in RAO could reasonably
comprise Holter monitoring and trans-esophageal echocar-
diography. [21, 23, 33, 43] A clinical trial of patients with
implanted devices capable of detecting silent episodes of
AF would contribute to furthering knowledge on the
Fig. 2 Cumulative incidence of atrial fibrillation and all-cause death according to retinal artery occlusion
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association of AF with subsequent risk of retinal vascular
occlusion.
We have previously shown how retinal vascular oc-
clusion (either RAO or RVO) is an independent and
substantial risk factor for stroke and thromboembolism in
patients with known AF. In this study of 87,000 patients
with AF, HR of RAO and RVO was 1.39 (1.08–1.79) and 1.
26 (1.02–1.54), respectively, after adjustment for cardiovas-
cular comorbidities and medication. [27]
In contrast to results from the present study, findings
from another study found an increased risk of AF in
patients with RVO, which may be explained by difference
between the study designs or ethnicity of the populations.
[44] Because RVO share risk factors with ischemic stroke,
RVO may be interpreted as a stroke surrogate marker.
[16] As such, AF detection in RVO may still be relevant
especially since AF commonly develops asymptomatically,
and the silent development of incident AF in patients with
prior retinal vascular occlusions would infer greater risk of
stroke in the absence of anticoagulation.
Since this is a registry-based cohort study, the results
represent an association between the two conditions
Fig. 3 Cumulative incidence of atrial fibrillation and all-cause death according to retinal vein occlusion
Fig. 4 Hazard ratio of AF according to retinal vascular occlusion shown as unadjusted as well as adjusted for hypertension, diabetes, vascular
disease and prior stroke/systemic thromboembolism/transitory ischemic attack. Reference is the corresponding controls without retinal
vascular occlusion
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rather than a causal relation. The hypothesis that sub-
clinical AF may be an underlying cause of RAO is sup-
ported by the significant increase in cumulative
incidence of AF amongst RAO patients compared to
controls. Comparably, no significant difference was
found between RVO and controls. This observed differ-
ence is also relevant when addressing the issue of detec-
tion bias: Because this is an observational study, patients
with retinal vascular occlusion conceivably receive
greater medical attention after study inclusion compared
with controls (i.e. surveillance bias), but the cumulative
incidence of AF did not differ between RVO patients
and controls, thereby countering the premise of surveil-
lance bias. Thus, the observed results support a hypoth-
esis of RAO, and not RVO, being caused by –
undiagnosed – silent AF.
As we did not have access to information about risk
factors such as obesity, excessive use of alcohol, the in-
crease in risk of incident AF in patients with RAO may
reflect a higher frequency of unmeasured risk factors as-
sociated with cardiovascular disease compared to con-
trols and patients with RVO. However, cumulative
incidence of death was similar in RVO and RAO pa-
tients, thereby implying that the increased risk of AF in
RAO – and not RVO – reflects a genuine association in-
dependent of differences in health status of cases and
controls.
Clinical implications
This study substantiates the importance of a careful
work-up required in patients with retinal vascular occlu-
sion, which is in accordance with other studies. [37, 45]
Detection of AF leads to indication for oral anticoagula-
tion (in the presence of at least one CHA2DS2-VASc
point) to efficiently reduce risk of ischemic stroke. [46,
47] Further studies are needed to estimate the effect of
oral anticoagulation on the risk of RAO.
Strengths and limitations
The primary strength of the study is the substantial size
of the cohort of patients diagnosed with retinal vascular
occlusion in Denmark between 1997 and 2011, and the
1:5 matched population without retinal vascular
occlusion.
However, only retinal vascular occlusions diagnosed in
hospitals were included, as we did not have access to
data regarding patients treated outside of hospitals. As
such, it is possible that the identified retinal vascular oc-
clusions treated in hospitals are more severe compared
to cases treated outside of hospitals. Consequently, if the
association between retinal vascular occlusion and AF is
more pronounced for more severe cases, our study may
overestimate this association.
Conclusions
In this nationwide cohort study of patients without pre-
vious AF or prior warfarin, we found that retinal vascu-
lar occlusions increased the risk of incident AF. In
subgroup analyses, the risk was increased in patients
with RAO but not in patients with RVO. As retinal vas-
cular occlusions increases the risk of thromboembolism
risk in patients with AF, vigilance for incident AF in pa-
tients with retinal vascular occlusions is recommended.
Abbreviation
AF: Atrial fibrillation; ATC: The Anatomical Therapeutic Chemical Classification
System; CHA2DS2-VASc: Congestive heart failure, hypertension, age >
75 years, diabetes, stroke, vascular disease, age 65–75 and female sex score;
CI: Confidence interval; HR: Hazard ratio; ICD: International Classification of
Diseases; IQR: Inter quartile range IQR; RAO: Retinal artery occlusion;
RVO: Retinal vein occlusion
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